The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Ulrika Ericson

Ulrika Ericson

Associate professor

Ulrika Ericson

Plasma Folate, Related Genetic Variants, and Colorectal Cancer Risk in EPIC


  • Simone J. P. M. Eussen
  • Stein Emil Vollset
  • Jannicke Igland
  • Klaus Meyer
  • Ase Fredriksen
  • Per Magne Ueland
  • Mazda Jenab
  • Nadia Slimani
  • Paolo Boffetta
  • Kim Overvad
  • Anne Tjonneland
  • Anja Olsen
  • Francoise Clavel-Chapelon
  • Marie-Christine Boutron-Ruault
  • Sophie Morois
  • Cornelia Weikert
  • Tobias Pischon
  • Jakob Linseisen
  • Rudolf Kaaks
  • Antonia Trichopoulou
  • Demosthenes Zilis
  • Michael Katsoulis
  • Domenico Palli
  • Franco Berrino
  • Paolo Vineis
  • Rosario Tumino
  • Salvatore Panico
  • Petra H. M. Peeters
  • H. Bas Bueno-de-Mesquita
  • Franzel J. B. van Duijnhoven
  • Inger Torhild Gram
  • Guri Skeie
  • Eiliv Lund
  • Carlos A. Gonzalez
  • Carmen Martinez
  • Miren Dorronsoro
  • Eva Ardanaz
  • Carmen Navarro
  • Laudina Rodriguez
  • Bethany Van Guelpen
  • Richard Palmqvist
  • Jonas Manjer
  • Ulrika Ericson
  • Sheila Bingham
  • Kay-Tee Khaw
  • Teresa Norat
  • Elio Riboli

Summary, in English

Background: A potential dual role of folate in colorectal cancer (CRC) is currently subject to debate. We investigate the associations between plasma folate, several relevant folate-related polymorphisms, and CRC risk within the large European Prospective Investigation into Cancer and Nutrition cohort. Methods: In this nested case-control study, 1,367 incident CRC cases were matched to 2,325 controls for study center, age, and sex. Risk ratios (RR) were estimated with conditional logistic regression and adjusted for smoking, education, physical activity, and intake of alcohol and fiber. Results: Overall analyses did not reveal associations of plasma folate with CRC. The RR (95% confidence interval; P-trend) for the fifth versus the first quintile of folate status was 0.94 (0.74-1.20; 0.44). The polymorphisms MTHFR677C -> T, MTHFR1298A -> C, MTR2756A -> G, MTRR66A -> G, and MTHFD11958G -> A were not associated with CRC risk. However, in individuals with the lowest plasma folate concentrations, the MTHFR 677TT genotype showed a statistically nonsignificant increased CRC risk [RR (95% CI; P-trend) TT versus CC = 1.39 (0.87-2.21); 0.12], whereas those with the highest folate concentrations showed a nonsignificant decreased CRC risk [RR TT versus CC = 0.74 (0.39-1.37); 0.34]. The SLC19A180G -> A showed a positive association with CRC risk [RR AA versus GG 1.30 (1.06-1.59); <0.01]. Conclusions: This large European prospective multicenter study did not show an association of CRC risk with plasma folate status nor with MTHFR polymorphisms. Impact: Findings of the present study tend to weaken the evidence that folate plays an important role in CRC carcinogenesis. However, larger sample sizes are needed to adequately address potential gene-environment interactions. Cancer Epidemiol Biomarkers Prev; 19(5); 1328-40. (C)2010 AACR.


  • Nutrition Epidemiology
  • EXODIAB: Excellence of Diabetes Research in Sweden
  • EpiHealth: Epidemiology for Health

Publishing year







Cancer Epidemiology Biomarkers & Prevention





Document type

Journal article


American Association for Cancer Research


  • Cancer and Oncology



Research group

  • Nutrition Epidemiology


  • ISSN: 1538-7755